Search Within

David Hyman

  1. "Gopakumar Iyer"
Formats
  1. Journal Article (11)
  2. Meeting Abstract (11)
Groups
  1. Department of Medicine (22)
  2. Early Drug Development Service (22)
  3. Genitourinary Oncology Service (22)
  4. Solid Tumor Oncology Division (22)
  5. Department of Pathology and Laboratory Medicine (16)
  6. Gynecologic Medicine Service (15)

More Groups

People
  1. Gopakumar Iyer (22)
  2. Michael Berger (13)
  3. David Solit (12)
  4. Jose Baselga (7)
  5. Rachel Grisham (7)
  6. Alexia Iasonos (6)

More People

Years
  1. 2020 (2)
  2. 2019 (2)
  3. 2018 (3)
  4. 2017 (5)
  5. 2015 (5)
  6. 2014 (2)

More Years

Publications
  1. Journal of Clinical Oncology (9)
  2. Annals of Oncology (2)
  3. Cancer Research (2)
  4. Cancer (1)
  5. Clinical Advances in Hematology & Oncology (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (10)
  2. American Association for Cancer Research (3)
  3. Nature Publishing Group (3)
  4. Oxford University Press (2)
  5. Lippincott Williams & Wilkins (1)
  6. Millennium Medical Publishing, Inc (1)

More Publishers

Results (22)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma
    Journal Article

    Teo, M. Y.; Bambury, R. M.; Zabor, E. C.; Jordan, E.; Al-Ahmadie, H.; Boyd, M. E.; Bouvier, N.; Mullane, S. A.; Cha, E. K.; Roper, N.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
    Journal Article

    Zehir, A.; Benayed, R.; Shah, R. H.; Syed, A.; Middha, S.; Kim, H. R.; Srinivasan, P.; Gao, J.; Chakravarty, D.; Devlin, S. M.; more...
    Nature Medicine (2017)

    Fulltext@MSK | Save
  • Ado-trastuzumab emtansine for HER2 amplified or HER2 overexpressed cancers: A phase II "basket" trial
    Meeting Abstract

    Li, B. T.; Zauderer, M.; Chaft, J.; Drilon, A.; Eng, J.; Sima, C.; Makker, V.; Iyer, G.; Janjigian, Y.; Hyman, D.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Functional genomics of HER2 and HER3 mutations and response to neratinib
    Meeting Abstract

    Hanrahan, A. J.; Hyman, D. M.; Sfakianos, J.; Jones, A.; Ramirez, R.; Johnsen, H.; Iyer, G.; Al-Ahmadie, H. A.; Bajorin, D.; Bochner, B. H.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer
    Journal Article

    Grisham, R. N.; Sylvester, B. E.; Won, H.; McDermott, G.; DeLair, D.; Ramirez, R.; Yao, Z.; Shen, R. L.; Dao, F.; Bogomolniy, F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Association of somatic mutations in DNA damage repair (DDR) genes with efficacy of platinum-based chemotherapy in advanced urothelial carcinoma
    Meeting Abstract

    Bambury, R. M.; Jordan, E.; Zabor, E. C.; Bouvier, N.; Al-Ahmadie, H.; Boyd, M. E.; Mullane, S. A.; Cha, E. K.; Ostrovnaya, I.; Hyman, D. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Comparison of genetic alterations from the bladder cancer genome atlas (TCGA) and a prospective set of high-grade urothelial carcinoma tumors using a CLIA laboratory next generation sequencing assay
    Meeting Abstract

    Iyer, G.; Bagrodia, A.; Cha, E. K.; Boyd, M. E.; Zehir, A.; Cheng, D. T.; Hyman, D. M.; Bambury, R. M.; Arcila, M. E.; Ladanyi, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer
    Journal Article

    Grisham, R. N.; Iyer, G.; Sala, E.; Zhou, Q.; Iasonos, A.; DeLair, D.; Hyman, D. M.; Aghajanian, C.
    International Journal of Gynecological Cancer (2014)

    Fulltext@MSK | Save
  • Targeted therapies for treatment of recurrent ovarian cancer
    Journal Article

    Grisham, R. N.; Hyman, D. M.; Iyer, G.
    Clinical Advances in Hematology & Oncology (2014)

    Fulltext@MSK | Save
  • Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    Meeting Abstract

    Grisham, R. N.; Sala, E.; Zhou, Q.; Iasonos, A.; DeLair, D.; Iyer, G.; Hyman, D. M.; Spriggs, D. R.; Aghajanian, C.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save